Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained.

Tytuł :
Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained.
Autorzy :
Ratushnyak S; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Center of Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation, Moscow, Russia.
Hoogendoorn M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
van Baal PHM; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
American journal of preventive medicine [Am J Prev Med] 2019 Dec; Vol. 57 (6), pp. 792-799.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: Amsterdam : Elsevier Science
Original Publication: [New York, NY] : Oxford University Press, [c1985-
MeSH Terms :
Cost-Benefit Analysis*
Quality-Adjusted Life Years*
Early Detection of Cancer/*economics
Mass Screening/*economics
Neoplasms/*prevention & control
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Health Care Costs ; Humans ; Male ; Middle Aged ; Neoplasms/complications ; Neoplasms/diagnosis ; Neoplasms/economics ; Quality of Life ; United States ; Young Adult
Entry Date(s) :
Date Created: 20191123 Date Completed: 20200831 Latest Revision: 20200831
Update Code :
20201023
DOI :
10.1016/j.amepre.2019.07.027
PMID :
31753260
Czasopismo naukowe
Introduction: Studies reporting on the cost-effectiveness of cancer screening usually account for quality of life losses and healthcare costs owing to cancer but do not account for future costs and quality of life losses related to competing risks. This study aims to demonstrate the impact of medical costs and quality of life losses of other diseases in the life years gained on the cost-effectiveness of U.S. cancer screening.
Methods: Cost-effectiveness studies of breast, cervical, and colorectal cancer screening in the U.S. were identified using a systematic literature review. Incremental cost-effectiveness ratios of the eligible articles were updated by adding lifetime expenditures and health losses per quality-adjusted life year gained because of competing risks. This was accomplished using data on medical spending and quality of life by age and disease from the Medical Expenditure Panel Survey (2011-2015) combined with cause-deleted life tables. The study was conducted in 2018.
Results: The impact of quality of life losses and healthcare expenditures of competing risks in life years gained incurred owing to screening were the highest for breast cancer and the lowest for cervical cancer. The updates suggest that incremental cost-effectiveness ratios are underestimated by $10,300-$13,700 per quality-adjusted life year gained if quality of life losses and healthcare expenditures of competing risks are omitted in economic evaluations. Furthermore, cancer screening programs that were considered cost saving, were found not to be so following the inclusion of medical expenditures of competing risks.
Conclusions: Practical difficulties in quantifying quality of life losses and healthcare expenditures owing to competing risks in life years gained can be overcome. Their inclusion can have a substantial impact on the cost-effectiveness of cancer screening programs.
(Copyright © 2019 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies